Ok folks, here's my general take on Biotimes currently
For almost two years straight we have been fluttering up and down with an average of $4. This is about to finally end.
Also for the last two years Biotime has been mostly still in R&D mode, and soon their regen therapeutics will be finishing up pre-clinicals. Partnerships with UCLA(stroke/growth factors) & Cornell(cancer diagnostics+anti-tumor) will soon become official IND's/products. Biotime also should announce another acquisition with the $9 MIL they have procured last month.
5 year chart says it all, a high of $10 in 2011 when Cornell/cancer diagnostic partnership was officially announced. Now three years later they are currently putting the final touches on what could be one of the worlds most extensive cancer diagnostic products....with a partner(Cornell) who's world renowned hospital will be the first to make use of it.
My feeling is that we might have a last chance here to buy in over the next week or two and that's it. Biotime will present a new video update on Tuesday concerning most likely their neural stem cell or cartilage regen progress.
Might be looking at one of the last dips Tuesday-Thursday if no official announcements commence.
Time to load up!